Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price & Analysis

259 Followers

VRCA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.77 - $9.22
Previous Close$4.62
Volume576.83K
Average Volume (3M)115.51K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$39.45M
Total Debt (Recent Filing)$1.59M
Price to Earnings (P/E)-4.5
Beta1.40
Next EarningsMar 02, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.02
Shares Outstanding41,094,053
R-Squared0.22
Standard Deviation0.24
10 Day Avg. Volume191,807
30 Day Avg. Volume115,511
Price to Book (P/B)3.91
Price to Sales (P/S)19.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-12.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside50.60% Upside
Rating ConsensusModerate Buy
Alpha-0.02
Number of Analyst Covering3


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

VRCA FAQ

What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $1.77 and its highest was $9.22 in the past 12 months.
    What is Verrica Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Verrica Pharmaceuticals’s upcoming earnings report date?
    Verrica Pharmaceuticals’s upcoming earnings report date is Mar 02, 2023 which is in 27 days.
      How were Verrica Pharmaceuticals’s earnings last quarter?
      Verrica Pharmaceuticals released its earnings results on Nov 07, 2022. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.105.
        Is Verrica Pharmaceuticals overvalued?
        According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Verrica Pharmaceuticals pay dividends?
          Verrica Pharmaceuticals does not currently pay dividends.
          What is Verrica Pharmaceuticals’s EPS estimate?
          Verrica Pharmaceuticals’s EPS estimate is -$0.19.
            How many shares outstanding does Verrica Pharmaceuticals have?
            Verrica Pharmaceuticals has 41,094,050 shares outstanding.
              What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
              Verrica Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -6.723%.
                Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
                Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 15M.

                  ---

                  Verrica Pharmaceuticals Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  -39.81%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -65.63%
                  Trailing 12-Months
                  Asset Growth
                  -44.63%
                  Trailing 12-Months
                  The Verrica Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Verrica Pharmaceuticals

                  Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Omeros
                  Trevi Therapeutics
                  IMARA
                  Lyra Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis